Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Non Operating Income (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Non Operating Income for 15 consecutive years, with $727000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 156.97% to $727000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.1 million, a 22.97% increase, with the full-year FY2024 number at -$1.7 million, down 9.29% from a year prior.
  • Non Operating Income was $727000.0 for Q3 2025 at Gyre Therapeutics, up from -$145000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $727000.0 in Q3 2025 to a low of -$1.3 million in Q3 2023.
  • A 5-year average of -$181533.3 and a median of -$20000.0 in 2021 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 168.0% in 2022, then plummeted 133200.0% in 2023.
  • Gyre Therapeutics' Non Operating Income stood at -$20000.0 in 2021, then skyrocketed by 95.0% to -$1000.0 in 2022, then crashed by 23600.0% to -$237000.0 in 2023, then plummeted by 82.7% to -$433000.0 in 2024, then skyrocketed by 267.9% to $727000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non Operating Income are $727000.0 (Q3 2025), -$145000.0 (Q2 2025), and -$433000.0 (Q4 2024).